TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026PRNewsWire · 2 days ago
A Look at TransMedics Group Inc (TMDX) After 3.1% Decline -- GF Value $160.75 vs Price $72.40GuruFocus · 3 days ago
Critical Review: TransMedics Group (NASDAQ:TMDX) & iRhythm Technologies (NASDAQ:IRTC)Defense World · Oct 18, 2026
TransMedics Group Inc (TMDX) Shares Fall 5.8% -- What GF Score of 74 Tells InvestorsGuruFocus · Oct 1, 2026
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?GuruFocus · Sep 26, 2026
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWire · Sep 26, 2026TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | $0.50 | $0.44 | Miss |
| May 5, 2026 | $0.62 | $0.30 | Miss |
| Feb 24, 2026 | $0.41 | $0.57 | Beat |
| Oct 29, 2025 | $0.37 | $0.66 | Beat |
| Jul 30, 2025 | $0.48 | $0.92 | Beat |
| May 8, 2025 | $0.29 | $0.70 | Beat |